10/17/2013

PathoGenetix said in a regulatory filing that it has secured $3.6 million as part of an equity financing round targeted at $9.1 million. The Woburn, Mass.-based firm, which develops products using its genome sequence scanning platform, did not disclose how it intends to use the money.

Related Summaries